NCT01767857: A trial that was reported late by Janssen Research & Development, LLC
This trial has reported, although it was 1027 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT01767857 |
|---|---|
| Title | Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | March 31, 2013 |
| Completion date | June 30, 2017 |
| Required reporting date | June 30, 2018, midnight |
| Actual reporting date | April 22, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | 1027 |